Assessment of the Cost Effectiveness of Travoprost versus Latanoprost as Single Agents for Treatment of Glaucoma in France

Payet, Stéphanie; Denis, Philippe; Berdeaux, G; Launois, R

doi:10.2165/00044011-200828030-00005

Cited by 10 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of the cost-effectiveness studies included in this systematic review retrieved effectiveness estimates from experimental sources, which is in line with most of the pharmacoeconomic recommendations (Heintz et al 2016;Zhao et al 2018). However, findings from RCT may differ from the real-world clinical practice due to the lack of representation of subpopulations, reduced sample sizes and reduced follow-up duration (Stang 2011;Payet et al 2008;Strom et al 2012). Therefore, these studies might not be able to provide relevant information for decision-makers (Payet et al 2008).…”

Section: Discussionmentioning

confidence: 91%

“…However, findings from RCT may differ from the real-world clinical practice due to the lack of representation of subpopulations, reduced sample sizes and reduced follow-up duration (Stang 2011;Payet et al 2008;Strom et al 2012). Therefore, these studies might not be able to provide relevant information for decision-makers (Payet et al 2008). Studies conducted under clinical practice conditions, such as Phase IV, pragmatic clinical trials and observational studies, which are aimed to assess the effectiveness of treatments, could be of great value in order to confirm the efficacy results obtained in RCTs (Alban et al 1997;AMCP 2016;Bastida et al 2010;CADTH 2017;Capri et al 2001;CES 2004;Fukuda 2016;Heintz et al 2016;Infarmed 1998; L€ a€ akkeiden Hintalautakunta 2017; Payet et al 2008;PHARMAC 2015;SMC, 2017;Studni cka et al 2013).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review

Ribeiro

Marques

Alves

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

Purpose: To characterize the effectiveness measures of cost-effectiveness studies (CES) of ophthalmic drugs. Methods: A systematic review was conducted in PubMed/Embase until October 2019. Cost-effectiveness studies (CES) evaluating ophthalmic drugs were included. Sources of effectiveness measures were extracted. Data on study design and study outcomes were extracted from sources of effectiveness measures. The adequacy of the sample size of the clinical studies used as sources of effectiveness measures was assessed. If CES have retrieved effectiveness data from multiple sources, the appropriateness of the method to combine the results was analysed. Results: Forty-five CES were included. Thirty-one (68.9%) retrieved their effectiveness measures from experimental studies, five (11.1%) from observational studies and nine (20%) from other type of data sources. Eight (17.8%) CES used data from a primary outcome of a study as an effectiveness measure, eight (17.8%) used data from secondary outcomes, seven (15.6%) used data from the both primary and secondary outcomes and for 22 (48.9%) it was not possible to identify the outcomes used. From the 23 (51.1%) CES based on a single clinical study, three (6.7%) included data from clinical studies which had an adequate sample size to detect significant differences in the clinical outcomes used as effectiveness measures. From the 17 (37.8%) CES based on multiple clinical studies, only one (2.2%) used and/or reported an adequate method of quantitative synthesis (metaanalysis). Conclusion: A considerable number of CES in ophthalmology were not based on clinical studies with adequate sample sizes and report results from effectiveness measures not assessed as primary outcomes.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review

Ribeiro

Marques

Alves

et al. 2020

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Among prostaglandin analogues, for example, tafluprost provides efficacy in IOP lowering in various settings, with improvements in OSD symptoms and patient satisfaction when compared with latanoprost 88–98. Travoprost and tafluprost monotherapies were suggested to be cost-effective relative to latanoprost alone 99,100. However, such drug–drug cost-effectiveness or budget impact studies are limited in developing countries.…”

Section: Objectives and Methodsmentioning

confidence: 99%

<p>Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement</p>

Delgado¹,

Abdelrahman²,

Terahi³

et al. 2019

CEOR

View full text Add to dashboard Cite

Glaucoma is the leading cause of blindness in the developed and developing world. Not only is the clinical impact of this disease considerable, but associated economic and humanistic burdens – affecting patients, caregivers, and society – are substantial. Since glaucoma is an age-related disorder and populations in many developing countries are aging at a faster pace than in the developed world, increasing attention is being focused on ways to ameliorate the burdens of illness. In this paper, we examine the burdens of glaucoma with particular focus on developing countries, discuss some of the challenges that exist in delivering optimal glaucoma management within budget constraints, and bring into perspective how we could improve current healthcare systems, leverage technology, and strike an appropriate balance between cost and quality of care, thereby offering considerations to payors and policymakers in these countries that may result in longer-term cost savings, while concurrently striving to achieve the WHO Vision on the prevention of blindness and visual impairment.

show abstract

“…In the literature, two Markov model-based health economic evaluations investigating the cost-effectiveness of Latanoprost in the French setting were identified. One compared Travoprost versus Latanoprost [51], whereas the second compared Travoprost to Latanoprost + Timolol [52]. Similar to the present study, both cost-effectiveness analyses adopted a 5-year time horizon.…”

Section: Probability Optimalmentioning

confidence: 99%

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Lazzaro¹,

Steen²,

Aptel

et al. 2022

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To investigate the cost utility of STN1013001, a latanoprost cationic emulsion, versus Latanoprost in patients with open-angle glaucoma or ocular hypertension (OAG/OHT) and concomitant ocular surface disease (OSD) in France. Methods. An early Markov model, including 7 health states and a 1-year cycle length, was developed to estimate the cost utility of STN1013001 versus Latanoprost from the French health system perspective over a 5-year time horizon. The model was populated with pooled data (treatment adherence, quality of life, disease progression, and resource utilization) collected, via a questionnaire, from a convenience sample of 5 French glaucoma specialists. Remaining data were retrieved from published sources. Half-cycle correction and 2.5% real social discount rate were applied to costs (in €2020), life years saved (LYS), and quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was contrasted against the informal willingness-to-pay (WTP) range for incremental LYS or QALY gained (€30,000–€50,000) suggested for France. One-way and probabilistic sensitivity analyses tested the robustness of the baseline ICUR. Results. Over a 5-year time horizon, STN1013001 resulted in an incremental 0.35 QALYs gained at an incremental cost of €7.39 compared to Latanoprost, resulting in an ICUR of €21.26. This is well below the lower limit of the unofficial WTP range proposed for France. Sensitivity analyses confirmed the robustness of the baseline results. Conclusion. Once on the market, STN1013001 will provide the French health system with a cost-effective treatment versus Latanoprost for OAG/OHT + OSD patients. These results should be confirmed by future economic evaluations carried out alongside empirical trials.

show abstract

Assessment of the Cost Effectiveness of Travoprost versus Latanoprost as Single Agents for Treatment of Glaucoma in France

Cited by 10 publications

References 46 publications

An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review

An analysis of the effectiveness outcomes of economic studies evaluating ophthalmic drugs: a systematic review

<p>Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement</p>

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Contact Info

Product

Resources

About